The Experts below are selected from a list of 201477 Experts worldwide ranked by ideXlab platform
Patrick O Monahan - One of the best experts on this subject based on the ideXlab platform.
-
patient health questionnaire anxiety and Depression Scale initial validation in three clinical trials
Psychosomatic Medicine, 2016Co-Authors: Kurt Kroenke, Jingwei Wu, Zhangsheng Yu, Matthew J Bair, Jacob Kean, Timothy E Stump, Patrick O MonahanAbstract:OBJECTIVE: We examine the reliability and validity of the Patient Health Questionnaire Anxiety and Depression Scale (PHQ-ADS)-which combines the nine-item Patient Health Questionnaire Depression Scale and seven-item Generalized Anxiety Disorder Scale-as a composite measure of Depression and anxiety. METHODS: Baseline data from 896 patients enrolled in two primary-care based trials of chronic pain and one oncology-practice-based trial of Depression and pain were analyzed. The internal reliability, standard error of measurement, and convergent, construct, and factor structure validity, as well as sensitivity to change of the PHQ-ADS were examined. RESULTS: The PHQ-ADS demonstrated high internal reliability (Cronbach α values of .8 to .9) in all three trials. PHQ-ADS scores can range from 0 to 48 (with higher scores indicating more severe Depression/anxiety), and the estimated standard error of measurement was approximately 3 to 4 points. The PHQ-ADS showed strong convergent (most correlations, 0.7-0.8 range) and construct (most correlations, 0.4-0.6 range) validity when examining its association with other mental health, quality of life, and disability measures. PHQ-ADS cutpoints of 10, 20, and 30 indicated mild, moderate, and severe levels of Depression/anxiety, respectively. Bifactor analysis showed sufficient unidimensionality of the PHQ-ADS score. PHQ-ADS change scores at 3 months differentiated (p < .0001) between individuals classified as worse, stable, or improved by a reference measure, providing preliminary evidence for sensitivity to change. CONCLUSIONS: The PHQ-ADS may be a reliable and valid composite measure of Depression and anxiety which, if validated in other populations, could be useful as a single measure for jointly assessing two of the most common psychological conditions in clinical practice and research. TRIAL REGISTRATION: Clinicaltrials.gov Identifier: NCT00926588 (SCOPE); NCT00386243 (ESCAPE); NCT00313573 (INCPAD).
-
Patient Health Questionnaire Anxiety and Depression Scale: Initial Validation in Three Clinical Trials.
Psychosomatic medicine, 2016Co-Authors: Kurt Kroenke, Matthew J Bair, Jacob Kean, Timothy E Stump, Patrick O MonahanAbstract:OBJECTIVE We examine the reliability and validity of the Patient Health Questionnaire Anxiety and Depression Scale (PHQ-ADS)-which combines the nine-item Patient Health Questionnaire Depression Scale and seven-item Generalized Anxiety Disorder Scale-as a composite measure of Depression and anxiety. METHODS Baseline data from 896 patients enrolled in two primary-care based trials of chronic pain and one oncology-practice-based trial of Depression and pain were analyzed. The internal reliability, standard error of measurement, and convergent, construct, and factor structure validity, as well as sensitivity to change of the PHQ-ADS were examined. RESULTS The PHQ-ADS demonstrated high internal reliability (Cronbach α values of .8 to .9) in all three trials. PHQ-ADS scores can range from 0 to 48 (with higher scores indicating more severe Depression/anxiety), and the estimated standard error of measurement was approximately 3 to 4 points. The PHQ-ADS showed strong convergent (most correlations, 0.7-0.8 range) and construct (most correlations, 0.4-0.6 range) validity when examining its association with other mental health, quality of life, and disability measures. PHQ-ADS cutpoints of 10, 20, and 30 indicated mild, moderate, and severe levels of Depression/anxiety, respectively. Bifactor analysis showed sufficient unidimensionality of the PHQ-ADS score. PHQ-ADS change scores at 3 months differentiated (p < .0001) between individuals classified as worse, stable, or improved by a reference measure, providing preliminary evidence for sensitivity to change. CONCLUSIONS The PHQ-ADS may be a reliable and valid composite measure of Depression and anxiety which, if validated in other populations, could be useful as a single measure for jointly assessing two of the most common psychological conditions in clinical practice and research. TRIAL REGISTRATION Clinicaltrials.gov Identifier: NCT00926588 (SCOPE); NCT00386243 (ESCAPE); NCT00313573 (INCPAD).
Alan Tennant - One of the best experts on this subject based on the ideXlab platform.
-
evaluation of the edinburgh post natal Depression Scale using rasch analysis
BMC Psychiatry, 2006Co-Authors: Julie F Pallant, Renee L Miller, Alan TennantAbstract:Background: The Edinburgh Postnatal Depression Scale (EPDS) is a 10 item self-rating post-natal Depression Scale which has seen widespread use in epidemiological and clinical studies. Concern has been raised over the validity of the EPDS as a single summed Scale, with suggestions that it measures two separate aspects, one of depressive feelings, the other of anxiety. Methods: As part of a larger cross-sectional study conducted in Melbourne, Australia, a community sample (324 women, ranging in age from 18 to 44 years: mean = 32 yrs, SD = 4.6), was obtained by inviting primiparous women to participate voluntarily in this study. Data from the EPDS were fitted to the Rasch measurement model and tested for appropriate category ordering, for item bias through Differential Item Functioning (DIF) analysis, and for unidimensionality through tests of the assumption of local independence. Results: Rasch analysis of the data from the ten item Scale initially demonstrated a lack of fit to the model with a significant Item-Trait Interaction total chi-square (chi Square = 82.8, df = 40; p < .001). Removal of two items (items 7 and 8) resulted in a non-significant Item-Trait Interaction total chisquare with a residual mean value for items of -0.467 with a standard deviation of 0.850, showing fit to the model. No DIF existed in the final 8-item Scale (EPDS-8) and all items showed fit to model expectations. Principal Components Analysis of the residuals supported the local independence assumption, and unidimensionality of the revised EPDS-8 Scale. Revised cut points were identified for EPDS-8 to maintain the case identification of the original Scale. Conclusion: The results of this study suggest that EPDS, in its original 10 item form, is not a viable Scale for the unidimensional measurement of Depression. Rasch analysis suggests that a revised eight item version (EPDS-8) would provide a more psychometrically robust Scale. The revised cut points of 7/8 and 9/10 for the EPDS-8 show high levels of agreement with the original case identification for the EPDS-10.
Jacob Kean - One of the best experts on this subject based on the ideXlab platform.
-
patient health questionnaire anxiety and Depression Scale initial validation in three clinical trials
Psychosomatic Medicine, 2016Co-Authors: Kurt Kroenke, Jingwei Wu, Zhangsheng Yu, Matthew J Bair, Jacob Kean, Timothy E Stump, Patrick O MonahanAbstract:OBJECTIVE: We examine the reliability and validity of the Patient Health Questionnaire Anxiety and Depression Scale (PHQ-ADS)-which combines the nine-item Patient Health Questionnaire Depression Scale and seven-item Generalized Anxiety Disorder Scale-as a composite measure of Depression and anxiety. METHODS: Baseline data from 896 patients enrolled in two primary-care based trials of chronic pain and one oncology-practice-based trial of Depression and pain were analyzed. The internal reliability, standard error of measurement, and convergent, construct, and factor structure validity, as well as sensitivity to change of the PHQ-ADS were examined. RESULTS: The PHQ-ADS demonstrated high internal reliability (Cronbach α values of .8 to .9) in all three trials. PHQ-ADS scores can range from 0 to 48 (with higher scores indicating more severe Depression/anxiety), and the estimated standard error of measurement was approximately 3 to 4 points. The PHQ-ADS showed strong convergent (most correlations, 0.7-0.8 range) and construct (most correlations, 0.4-0.6 range) validity when examining its association with other mental health, quality of life, and disability measures. PHQ-ADS cutpoints of 10, 20, and 30 indicated mild, moderate, and severe levels of Depression/anxiety, respectively. Bifactor analysis showed sufficient unidimensionality of the PHQ-ADS score. PHQ-ADS change scores at 3 months differentiated (p < .0001) between individuals classified as worse, stable, or improved by a reference measure, providing preliminary evidence for sensitivity to change. CONCLUSIONS: The PHQ-ADS may be a reliable and valid composite measure of Depression and anxiety which, if validated in other populations, could be useful as a single measure for jointly assessing two of the most common psychological conditions in clinical practice and research. TRIAL REGISTRATION: Clinicaltrials.gov Identifier: NCT00926588 (SCOPE); NCT00386243 (ESCAPE); NCT00313573 (INCPAD).
-
Patient Health Questionnaire Anxiety and Depression Scale: Initial Validation in Three Clinical Trials.
Psychosomatic medicine, 2016Co-Authors: Kurt Kroenke, Matthew J Bair, Jacob Kean, Timothy E Stump, Patrick O MonahanAbstract:OBJECTIVE We examine the reliability and validity of the Patient Health Questionnaire Anxiety and Depression Scale (PHQ-ADS)-which combines the nine-item Patient Health Questionnaire Depression Scale and seven-item Generalized Anxiety Disorder Scale-as a composite measure of Depression and anxiety. METHODS Baseline data from 896 patients enrolled in two primary-care based trials of chronic pain and one oncology-practice-based trial of Depression and pain were analyzed. The internal reliability, standard error of measurement, and convergent, construct, and factor structure validity, as well as sensitivity to change of the PHQ-ADS were examined. RESULTS The PHQ-ADS demonstrated high internal reliability (Cronbach α values of .8 to .9) in all three trials. PHQ-ADS scores can range from 0 to 48 (with higher scores indicating more severe Depression/anxiety), and the estimated standard error of measurement was approximately 3 to 4 points. The PHQ-ADS showed strong convergent (most correlations, 0.7-0.8 range) and construct (most correlations, 0.4-0.6 range) validity when examining its association with other mental health, quality of life, and disability measures. PHQ-ADS cutpoints of 10, 20, and 30 indicated mild, moderate, and severe levels of Depression/anxiety, respectively. Bifactor analysis showed sufficient unidimensionality of the PHQ-ADS score. PHQ-ADS change scores at 3 months differentiated (p < .0001) between individuals classified as worse, stable, or improved by a reference measure, providing preliminary evidence for sensitivity to change. CONCLUSIONS The PHQ-ADS may be a reliable and valid composite measure of Depression and anxiety which, if validated in other populations, could be useful as a single measure for jointly assessing two of the most common psychological conditions in clinical practice and research. TRIAL REGISTRATION Clinicaltrials.gov Identifier: NCT00926588 (SCOPE); NCT00386243 (ESCAPE); NCT00313573 (INCPAD).
Mitch Earleywine - One of the best experts on this subject based on the ideXlab platform.
-
validation of the center for epidemiologic studies Depression Scale revised cesd r pragmatic Depression assessment in the general population
Psychiatry Research-neuroimaging, 2011Co-Authors: Nicholas T Van Dam, Mitch EarleywineAbstract:Abstract Depression has a huge societal impact, making accurate measurement paramount. While there are several available measures, the Center for Epidemiological Studies Depression Scale (CESD) is a popular assessment tool that has wide applicability in the general population. In order to reflect modern diagnostic criteria and improve upon psychometric limitations of its predecessor, the Center for Epidemiologic Studies Depression Scale Revised (CESD-R) was recently created, but has yet to be publicized. This study explored psychometric properties of the CESD-R across a large community sample ( N =7389) and smaller student sample ( N =245). A newly proposed algorithmic classification method yielded base-rates of Depression consistent with epidemiological results. Factor analysis suggested a unidimensional factor structure, but important utility for two separate symptom clusters. The CESD-R exhibited good psychometric properties, including high internal consistency, strong factor loadings, and theoretically consistent convergent and divergent validity with anxiety, schizotypy, and positive and negative affect. Results suggest the CESD-R is an accurate and valid measure of Depression in the general population with advantages such as free distribution and an atheoretical basis.
-
validation of the center for epidemiologic studies Depression Scale revised cesd r pragmatic Depression assessment in the general population
Psychiatry Research-neuroimaging, 2011Co-Authors: Mitch EarleywineAbstract:Abstract Depression has a huge societal impact, making accurate measurement paramount. While there are several available measures, the Center for Epidemiological Studies Depression Scale (CESD) is a popular assessment tool that has wide applicability in the general population. In order to reflect modern diagnostic criteria and improve upon psychometric limitations of its predecessor, the Center for Epidemiologic Studies Depression Scale Revised (CESD-R) was recently created, but has yet to be publicized. This study explored psychometric properties of the CESD-R across a large community sample ( N =7389) and smaller student sample ( N =245). A newly proposed algorithmic classification method yielded base-rates of Depression consistent with epidemiological results. Factor analysis suggested a unidimensional factor structure, but important utility for two separate symptom clusters. The CESD-R exhibited good psychometric properties, including high internal consistency, strong factor loadings, and theoretically consistent convergent and divergent validity with anxiety, schizotypy, and positive and negative affect. Results suggest the CESD-R is an accurate and valid measure of Depression in the general population with advantages such as free distribution and an atheoretical basis.
Kurt Kroenke - One of the best experts on this subject based on the ideXlab platform.
-
patient health questionnaire anxiety and Depression Scale initial validation in three clinical trials
Psychosomatic Medicine, 2016Co-Authors: Kurt Kroenke, Jingwei Wu, Zhangsheng Yu, Matthew J Bair, Jacob Kean, Timothy E Stump, Patrick O MonahanAbstract:OBJECTIVE: We examine the reliability and validity of the Patient Health Questionnaire Anxiety and Depression Scale (PHQ-ADS)-which combines the nine-item Patient Health Questionnaire Depression Scale and seven-item Generalized Anxiety Disorder Scale-as a composite measure of Depression and anxiety. METHODS: Baseline data from 896 patients enrolled in two primary-care based trials of chronic pain and one oncology-practice-based trial of Depression and pain were analyzed. The internal reliability, standard error of measurement, and convergent, construct, and factor structure validity, as well as sensitivity to change of the PHQ-ADS were examined. RESULTS: The PHQ-ADS demonstrated high internal reliability (Cronbach α values of .8 to .9) in all three trials. PHQ-ADS scores can range from 0 to 48 (with higher scores indicating more severe Depression/anxiety), and the estimated standard error of measurement was approximately 3 to 4 points. The PHQ-ADS showed strong convergent (most correlations, 0.7-0.8 range) and construct (most correlations, 0.4-0.6 range) validity when examining its association with other mental health, quality of life, and disability measures. PHQ-ADS cutpoints of 10, 20, and 30 indicated mild, moderate, and severe levels of Depression/anxiety, respectively. Bifactor analysis showed sufficient unidimensionality of the PHQ-ADS score. PHQ-ADS change scores at 3 months differentiated (p < .0001) between individuals classified as worse, stable, or improved by a reference measure, providing preliminary evidence for sensitivity to change. CONCLUSIONS: The PHQ-ADS may be a reliable and valid composite measure of Depression and anxiety which, if validated in other populations, could be useful as a single measure for jointly assessing two of the most common psychological conditions in clinical practice and research. TRIAL REGISTRATION: Clinicaltrials.gov Identifier: NCT00926588 (SCOPE); NCT00386243 (ESCAPE); NCT00313573 (INCPAD).
-
Patient Health Questionnaire Anxiety and Depression Scale: Initial Validation in Three Clinical Trials.
Psychosomatic medicine, 2016Co-Authors: Kurt Kroenke, Matthew J Bair, Jacob Kean, Timothy E Stump, Patrick O MonahanAbstract:OBJECTIVE We examine the reliability and validity of the Patient Health Questionnaire Anxiety and Depression Scale (PHQ-ADS)-which combines the nine-item Patient Health Questionnaire Depression Scale and seven-item Generalized Anxiety Disorder Scale-as a composite measure of Depression and anxiety. METHODS Baseline data from 896 patients enrolled in two primary-care based trials of chronic pain and one oncology-practice-based trial of Depression and pain were analyzed. The internal reliability, standard error of measurement, and convergent, construct, and factor structure validity, as well as sensitivity to change of the PHQ-ADS were examined. RESULTS The PHQ-ADS demonstrated high internal reliability (Cronbach α values of .8 to .9) in all three trials. PHQ-ADS scores can range from 0 to 48 (with higher scores indicating more severe Depression/anxiety), and the estimated standard error of measurement was approximately 3 to 4 points. The PHQ-ADS showed strong convergent (most correlations, 0.7-0.8 range) and construct (most correlations, 0.4-0.6 range) validity when examining its association with other mental health, quality of life, and disability measures. PHQ-ADS cutpoints of 10, 20, and 30 indicated mild, moderate, and severe levels of Depression/anxiety, respectively. Bifactor analysis showed sufficient unidimensionality of the PHQ-ADS score. PHQ-ADS change scores at 3 months differentiated (p < .0001) between individuals classified as worse, stable, or improved by a reference measure, providing preliminary evidence for sensitivity to change. CONCLUSIONS The PHQ-ADS may be a reliable and valid composite measure of Depression and anxiety which, if validated in other populations, could be useful as a single measure for jointly assessing two of the most common psychological conditions in clinical practice and research. TRIAL REGISTRATION Clinicaltrials.gov Identifier: NCT00926588 (SCOPE); NCT00386243 (ESCAPE); NCT00313573 (INCPAD).